Fierce Pharma
Trinity’s Krista Perry, Partner & Head of Launch Excellence, was featured in an article by Fierce Pharma to discuss our latest white paper, Moving the Needle: Lessons from the 2023 Launch Class. Read the article to learn more about what factors contribute to a successful drug launch.
Read Now…
Read Now
The Pharma Letter
Trinity Life Sciences’ recent white paper on the first year performance of the 2023 launch class was featured in an article published on The Pharma Letter.
Read Now…
Read Now
Pharmaceutical Market Europe
Trinity’s recent white paper, Picking Winners: Portfolio Management for a New Era, was mentioned in a recent article by Pharmaceutical Market Europe.
Read Now…
Read Now
The Pharma Letter
The biopharma industry is intensely competitive, and companies must go to great lengths to gain any commercial edge. However, it is also an industry that sees more failure than success. Leslie Orne, President & CEO of Trinity Life Sciences, provides an expert view in The Pharma Letter on how biopharma companies can make the best choices to achieve commercial success.
Read Now…
Read Now
MM+M Podcast
Trinity Life Science’s Monica Martin De Bustamante analyzes the Medicare-negotiated prices of the first 10 drugs under the Inflation Reduction Act.
Listen Now…
Read Now
Boston Business Journal
Check out Nancy Phelan’s profile in the Boston Business Journal.
Read Now…
Read Now
Pharmaceutical Executive
It’s clear that there is still work to be done with regard to diversity in clinical trials. Lisa Bailey, Managing Director and Head of DEI Strategy at Trinity Life Sciences, shares her insights with Pharmaceutical Executive on the lack of diversity in trials and how the industry can work to solve this problem.
Read Now…
Read Now
MedCity News
“While FDA approval has long been a singular prize, companies should also mine their assets for the strongest commercial opportunities. …the ability to take a drug to market is an important milestone, but it is not the entire picture. To truly move the needle, both clinically and commercially, biopharma companies must fine-tune their teams, approaches and incentives to produce unique and innovative products.”Read more from Leslie Orne’s new op-ed in MedCity News entitled, “Balancing Risk and Opportunities to Choose Winning…
Read Now
Black Doctor
Trinity Life Sciences’ recent white paper on diversity in clinical trials was mentioned in an article published on Black Doctor.
Read Now…
Read Now
Fierce Biotech
Fierce Biotech mentioned Trinity Life Sciences’ recent white paper, Diversity in Clinical Trials: Life Sciences Initiatives and Challenges in Light of the FDA’s Latest Guidance, in their coverage of the updated FDA guidance.
Read Now…
Read Now